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Abstract
Two premature twins (33 weeks gestation) were born to a woman who had used paroxetine during pregnancy for
an anxiety-depression disorder. They were admitted to the NICU, where they showed prolonged RDS, cardiovascu-
lar malformations, and facial dysmorphisms. Soon after birth, they also presented abnormal neurobehavioral and
motor signs, which partially disappeared during the following weeks, although alterations of tone persisted even at
discharge.
Selective serotonin reuptake inhibitor (SSRI) antidepressants are considered the primary treatments for depression
and anxiety in pregnancy. Since intrauterine exposure to these drugs has been associated with poor neonatal
adaptation, low birth weight, RDS, neurobehavioural symptoms, and potential teratogenic effects, further studies
are needed to assess risks and mechanism of action of SSRIs. Meanwhile, it is advisable to evaluate for each patient
the real risk/benefit ratio of continuing or suspending treatment during pregnancy.
Introduction
Recent studies report that depression and anxiety disor-
ders affect 12-18% and 1.5-5% of pregnant women,
respectively [1]. Selective serotonin reuptake inhibitor
(fluoxetine, paroxetine, sertraline, etc) are considered
the primary treatments for these disorders. In recent
years several concerns have been raised about safety of
some antidepressants during pregnancy.
In utero exposure to an SSRI has been associated with
many neonatal symptoms, including respiratory distress,
feeding difficulties, and a wide spectrum of neurological
symptoms. A neonatal abstinence syndrome (NAS),
resulting from exposure to SSRIs during pregnancy, may
explain this clinical syndrome, characterized by central
nervous system, gastrointestinal, autonomic and respira-
tory symptoms [2,3]. In a cohort study, symptoms of
NAS were present in 30% of exposed infants compared
to none of the non-exposed control infants [4].
Furthermore, concerns regarding persistent pulmonary
hypertension, teratogenic risks, and neonatal adaptation
have also been raised. In particular, recent studies have
indicated an increased prevalence of certain malforma-
tions, as omphalocele, craniosynostosis, and, more
consistently, heart defects in newborns exposed to SSRIs
in utero [4-8].
We here report details of two premature twins who,
after in uteroexposure to SSRIs, presented symptoms
compatible with the NAS and cardiovascular
malformations.
Case Report
We describe the case of two monozygotic, naturally
conceived, twin girls born by cesarean section at 33
weeks gestation for premature rupture of membranes.
Birth weights were 1420 (10-25th percentile) and 1250 g
(<3rd percentile). Pregnancy was complicated by polihy-
droamnios and gestational diabetes. The mother had
used paroxetine 5 and 20 mg/day for the first 2 months
and last 3 weeks of gestation, respectively, for an anxi-
ety-depression disorder. Ultrasound at 20 weeks gesta-
tion had shown right aortic arch in the first twin and a
single umbilical artery in the second twin. Familial his-
tory was negative for congenital malformations or
genetic disorders.
At birth both newborns presented cardiorespiratory
depression and therefore were intubated and admitted
to the NICU. They both received one dose of surfactant
and, after extubation, were treated with CPAP through
nasal prongs. Initial physical examination showed facial
dysmorphisms, involving hypertelorism, proptosic eyes,
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hypoplasic nasal pyramide, wide antiverse nostrils. Dur-
ing the second day of life, the newborns also developed
neurobehavioral and motor signs (hyperreactivity, irrit-
ability, jitteriness, hyperextension of the trunk and limbs
with worsening of dyspnea during manipulations).
Echocardiograms in the first twin confirmed a right
aortic arch and documented in both patients moderate
valvular pulmonary stenosis and small ostium secun-
dum. Cerebral ultrasound was normal in the first twin,
while the second presented bilateral parietal hyperecho-
genic spots, which had disappeared at the first post-
discharge ultrasound. Hemochrome, plasma electrolytes,
glycemia, C-reactive protein, urine exam, and hemocol-
ture excluded inflammatory/infectious and metabolic
disorders. Kariotypes were normal in both twins.
In the following days they remained quite unstable
and required n-CPAP for 34 and 28 days. Oxygen-ther-
apy was continued till the 52nd and 55th day, respec-
tively. Neurobehavioral and motor signs decreased
slowly during the following weeks.
At discharge at 95 days the first twin presented hyper-
tone at the lower limbs and the second a hypotonic syn-
drome with mild developmental delay in motor
acquisitions; both had mild retractions, tachypnea and
nasal congestion. Echocardiograms confirmed the pre-
sence of moderate valvular pulmonary stenosis.
At 6 months follow-up, the twins showed an adequate
psychomotor development with resolution of neurobe-
havioral and respiratory symptoms.
Discussion
Exposure to SSRIs has been associated with poor neona-
tal adaptation, low birth weight and a clinical picture
characterized by neurobehavioral, gastrointestinal,
respiratory and somatic symptoms [2]. These findings
have stimulated studies regarding their use in pregnancy
and possible effects on fetus and newborn.
In literature, the most common neurobehavioral
symptoms described in exposed newborns are: hypo or
hypertonia, hyperreflexia, tremor, jitteriness, irritability,
constant crying, agitation, spasms, seizures, and sleep
disturbances. Higher rates of vomiting, diarrhoea, tachy-
cardia, hypoglycemia, feeding difficulty, hyper or
hypothermia and jaundice have also been described
[9,10].
As of November 2001, the FDA Adverse Event
Reporting System contained 210 possible SRI-related
neonatal behavioural syndrome cases, of which 57 met
criteria for FDA case definition of NAS, and 37 seemed
to be consistent with an acute neonatal toxicity
syndrome [9].
In the withdrawal syndrome sleep disturbances, neuro-
logical, gastrointestinal, motor, and somatic changes are
most frequent. Onset is between 2 days to 1 month
from birth, and duration of symptoms is less than 2
weeks [10]. The toxicity syndrome is characterized by
symptoms which appear within the first hours after
birth and usually present as neurobehavioral changes
and respiratory difficulties (retractions, apnea/bradycar-
dia, cyanosis, tachypnea and nasal congestion) [11].
While neurobehavioral, gastrointestinal and somatic
manifestations are quite similar to those seen in adults
assuming SSRIs, the respiratory problems, which may
require prolonged hospitalization and ventilatory sup-
port, are not easily explained. Epidemiological and
experimental data suggest an association between mater-
nal use of SSRIs and the prevalence of persistent pul-
monary hypertension of the newborn [12,13]. However
it is not easy to establish to which extent neonatal
respiratory symptoms in exposed newborns are related
to pulmonary hypertension.
In this case report we were not able to assess whether
respiratory symptoms result either from a serotoninergic
syndrome or simply from prematurity. The twins’ gesta-
tional age does not explain such a prolonged RDS; on
the other hand, there is evidence that preterms, born to
mothers assuming SSRIs during pregnancy, are more
susceptible to the effects of these drugs than term new-
borns. A recent retrospective cohort study demonstrated
a higher prevalence of behavioral (100% vs 69.1%) and
respiratory symptoms (66.7% vs 25.5%) and a longer
median length of stay in preterm newborns compared to
term newborns (14.5 vs 3.6 days) [10]. Furthermore, as
described in literature, the rate of prematurity itself was
higher in the exposed group compared to a group of
unexposed infants.
Our twins obviously had other reasons to be born pre-
maturely (i.e. severe polihydroamnios), but we cannot
exclude that paroxetine may have contributed.
The risk of malformations after antenatal exposure to
SSRIs remains controversial [14]. While early studies
excluded major teratogenic effects of these drugs, in
recent years associations between the exposure to speci-
fic SSRIs and selected malformations have been reported
[5,6,15]. In particular an analysis of the association
between specific birth defects and first trimester expo-
sure to paroxetine showed a significant increase in right
ventricular outflow tract obstruction [7]. The clinical
history of our twins characterized by an exposure of 7-8
weeks, during the first trimester, and presence of pul-
monary stenosis is consistent with these previous find-
ings. However, large, prospective studies are warranted
to assess the teratogenic potential of SSRIs and answer
this relevant safety question.
In order to prevent SSRI syndrome in newborns it has
been suggested to taper or discontinue treatment 2
weeks prior to delivery, with resumption after birth [12].
This approach is not always applicable because of
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unpredictability of birth timing and risk of recurrence of
maternal disease, which may complicate pregnancy.
Another possibility could be continuation of maternal
treatment with the SSRI during breastfeeding, which is
not contraindicated, but requires close monitoring for
neonatal symptoms [16]. Monitoring serum levels of the
drugs during breastfeeding is not possible in most hos-
pitals, as in ours; therefore we believe that clinical
observation is more important.
A therapeutic approach to newborns exposed to SSRI
must include a quiet environment with minimal stimula-
tion with lights, noises, or handling. Close cardiorespira-
tory monitoring and Finnegan Score assessment are
recommended. Sedatives and anticonvulsants are sel-
domly required. Nordeng et al. described 3 paroxetine
exposed newborns, who were treated with chlorproma-
zine, known to have sedative and antiserotoninergic
effects. In one case treatment was interrupted because
of side effects, while in the other two cases an almost
complete resolution of symptoms was obtained [17].
Although concerns raised about possible neonatal
risks associated with SSRI exposure during pregnancy
are appropriate, the potential risks of depression and/or
anxiety on maternal and neonatal well-being must not
be underestimated. Indeed there is evidence that
untreated psychiatric disorders may have unfavourable
outcomes for both mother and newborn [2].
Information about safety profiles of SSRIs during
pregnancy is limited and mostly due to post-marketing
experience, but, since these drugs are the most widely
used antidepressants in pregnancy, further studies are
needed to assess risks and mechanisms of action. Cur-
rently it is advisable to use the lowest dosage possible,
avoid multitherapy approaches and evaluate risk/benefit
ratios of both continuing or suspending treatment dur-
ing pregnancy in each single patient.
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